- $69.38m
- -$1.03m
- 42
- 32
- 25
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.13% | ||
| Return on Equity | -80.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Directors
- Punit Dhillon CHM (40)
- Kaitlyn Arsenault CFO
- Tu Diep OTH
- Margaret Dalesandro IND (75)
- James Heppell IND (65)
- Praveen Tyle IND (61)
- Keith Ward IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 16th, 2011
- Public Since
- February 24th, 2014
- No. of Shareholders
- 190
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 30,974,559
- Address
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, 92130
- Web
- https://skyebioscience.com/
- Phone
- +1 8584100266
- Auditors
- Marcum LLP
Upcoming Events for SKYE
Q1 2025 Skye Bioscience Inc Earnings Release
Skye Bioscience Inc at Craig-Hallum Institutional Investor Conference
Q2 2025 Skye Bioscience Inc Earnings Release
Similar to SKYE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Skye Bioscience share price?
As of Today at 23:18 UTC, shares in Skye Bioscience are trading at $2.24. This share price information is delayed by 15 minutes.
How has the Skye Bioscience share price performed this year?
Shares in Skye Bioscience last closed at $2.24 and the price had moved by -82.76% over the past 365 days. In terms of relative price strength the Skye Bioscience share price has underperformed the S&P500 Index by -84.45% over the past year.
What are the analyst and broker recommendations for Skye Bioscience?
The overall consensus recommendation for Skye Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Skye Bioscience dividend yield?
Skye Bioscience does not currently pay a dividend.
Does Skye Bioscience pay a dividend?
Skye Bioscience does not currently pay a dividend.
When does Skye Bioscience next pay dividends?
Skye Bioscience does not currently pay a dividend.
How do I buy Skye Bioscience shares?
To buy shares in Skye Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Skye Bioscience?
As of the previous close price of $2.24, shares in Skye Bioscience had a market capitalisation of $69.38m.
Where are Skye Bioscience shares listed?
Here are the trading details for Skye Bioscience:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SKYE
What kind of share is Skye Bioscience?
Based on an overall assessment of its quality, value and momentum Skye Bioscience is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Skye Bioscience share price forecast for 2025?
The analyst consensus target price for shares in Skye Bioscience is $17.33. That is 673.66% above the last closing price of $2.24.
Analysts covering Skye Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$1.20 for the next financial year.
Find out moreWhat is the trend in the Skye Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Skye Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -59.53%.
As of the last closing price of $2.24, shares in Skye Bioscience were trading -40.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Skye Bioscience PE Ratio?
The Skye Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Skye Bioscience?
Skye Bioscience's management team is headed by:
- Punit Dhillon - CHM
- Kaitlyn Arsenault - CFO
- Tu Diep - OTH
- Margaret Dalesandro - IND
- James Heppell - IND
- Praveen Tyle - IND
- Keith Ward - IND